Morgan Stanley maintains Buy at AUD 182.00 for CSL stock

Published on 10/13/2026 at 10:17 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Morgan Stanley keeps Buy and targets AUD 182.00 on October 11, 2026. CSL stock costs EUR 114.74 between EUR 114.12 bid and EUR 115.36 ask.

Morgan Stanley maintained a Buy rating and an AUD 182.00 price target for CSL on October 11, 2026.
CSL agreed to pay USD 355.0 million upfront for lixudebart rights, with up to USD 1.2 billion in milestones.
CSL stock was at EUR 114.74 at Lang & Schwarz on October 13, 2026, while CSL's ASX market capitalization was AUD 88.4 billion.
CSL's annual general meeting is scheduled for October 27, 2026, in Melbourne.

CSL, AU000000CSL8, Illustration mit AI erstellt.

CSL Limited (ISIN AU000000CSL8) was at EUR 114.74 at Lang & Schwarz on October 13, 2026 at 10:08 a.m. CEST, while Morgan Stanley maintained a Buy rating and an AUD 182.00 price target in a report dated October 11, 2026, according to Markets Insider. The analyst action gives the stock a clear valuation reference as CSL develops a new rare-disease pipeline.

Three recent valuation signals

On September 23, 2026, Citi maintained a Hold rating and an AUD 160.00 price target for CSL, as reported by Markets Insider. The range of published targets shows why the current AUD 182.00 Morgan Stanley view is a specific analyst stance rather than a market-wide estimate.

On October 5, 2026, CSL announced an exclusive collaboration with Alentis Therapeutics for lixudebart. The agreement includes a USD 355.0 million upfront payment, up to USD 1.2 billion in commercial milestones and a 55 percent share of global profits for CSL, according to CSL.

What does the deal add?

Lixudebart is being evaluated in a Phase 2 trial for ANCA-associated vasculitis with rapidly progressive glomerulonephritis, while planned development also covers focal segmental glomerulosclerosis and primary sclerosing cholangitis. The source release cites interim data from 26 patients in the kidney study and 41 patients in a liver-fibrosis study, but the drug remains investigational.

ASX valuation and next date

CSL was last at AUD 184.58 on the ASX on October 13, 2026 at 4:10 p.m. AEST. Its 52-week range was AUD 90.00 to AUD 222.47, and its market capitalization was AUD 88.4 billion on the same date. The figures put the stock 17.03 percent below its 52-week high, calculated from the ASX values.

TipRanks reported that CSL will hold its annual general meeting on October 27, 2026, at 10:00 a.m. AEDT in Melbourne. The meeting is the next dated corporate event identified for shareholders.

CSL stock stays in a wide range

At Lang & Schwarz, the intraday quote stood at EUR 114.74 on October 13, 2026 at 10:08 a.m. CEST. The bid was EUR 114.12 and the ask was EUR 115.36, giving investors a narrow real-time trading corridor around the reference price. The further course of trading is shown by the continuously updated real-time quote of CSL stock.